Slide 1: Compugen Reports Second Quarter 2026 Results
Compugen Reports Second Quarter 2026 Results COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO Gynaecological Cancers Congress 2026, reinforcing the
Slide 2: COM701, Rilvegostomig, GS-0321 and Early Pipeline Updates
The Company believes that clear prolongation of PFS in these patients versus placebo could inform a registration path for COM701 and establish it as a potential backbone for drug combinations. Clinically meaningful success could also enable a broader clinical development plan across earlier and late
Slide 3: Second Quarter 2026 Financial Highlights and Conference Call
Revenues for the second quarter of 2026 were approximately $2.6 million, compared to approximately $1.3 million for the comparable period in 2025. Revenues in the second quarters of 2026 and 2025 reflect the recognition of portions of both the upfront payment and the IND milestone payment from the
Slide 4: Forward-looking statements
This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the curr
Slide 5: Contact details
Email: lindseyt@cgen.com Tel: +1 (628) 241-0071
Slide 6: Condensed Consolidated Statements of Operations
COMPUGEN LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except for share and per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Unaudited Unaudited Unaudited Unaudited Revenues 2,602 1,257 4,778 3,541 Cost of revenues 2,694
Slide 7: Condensed Consolidated Balance Sheets Data
COMPUGEN LTD. CONDENSED CONSOLIDATED BALANCE SHEETS DATA (U.S. dollars in thousands) June 30, December 31, 2026 2025 Unaudited ASSETS Current assets Cash and cash equivalents 10,280 90,597 Short-term bank deposits 75,338 45,759 Investment in marketable securities 39,682 9,284 Accounts receivable 680